|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-3-19
|
|
pubmed:abstractText |
Monthly oral ibandronate is indicated for the prevention and treatment of osteoporosis in postmenopausal women. The STudy Researching Osteoporosis iN Guys (STRONG) investigated the efficacy and safety of 150-mg monthly oral ibandronate in men with primary, idiopathic, or hypogonadism-related low bone density.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1873-2763
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2009 Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
46
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
970-6
|
|
pubmed:meshHeading |
pubmed-meshheading:20060082-Absorptiometry, Photon,
pubmed-meshheading:20060082-Aged,
pubmed-meshheading:20060082-Alkaline Phosphatase,
pubmed-meshheading:20060082-Biological Markers,
pubmed-meshheading:20060082-Bone Density,
pubmed-meshheading:20060082-Bone Density Conservation Agents,
pubmed-meshheading:20060082-Collagen Type I,
pubmed-meshheading:20060082-Diphosphonates,
pubmed-meshheading:20060082-Double-Blind Method,
pubmed-meshheading:20060082-Drug Administration Schedule,
pubmed-meshheading:20060082-Humans,
pubmed-meshheading:20060082-Intention to Treat Analysis,
pubmed-meshheading:20060082-Male,
pubmed-meshheading:20060082-Middle Aged,
pubmed-meshheading:20060082-Osteoporosis,
pubmed-meshheading:20060082-Peptides,
pubmed-meshheading:20060082-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Efficacy and safety of monthly ibandronate in men with low bone density.
|
|
pubmed:affiliation |
Oregon Health and Science University, Bone and Mineral Unit, Portland, OR 97239, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|
